Pazdur’s Post-Mortem On ‘Dangling’ Accelerated Approvals: Message At ODAC Was Heard Loud And Clear
The three-day advisory committee was intended to ‘put companies on notice’ about the importance of confirmatory trials. The result? Mission accomplished.
You may also be interested in...
China-Only Studies Are ‘Problematic,’ US FDA’s Pazdur Says Ahead Of Lilly/Innovent PD-1 Inhibitor Review
February advisory committee for sintilimab expected to address three main questions about applications relying on single-country data.
Project Orbis Nears 30 Approvals In Oncology; Could China Be Added?
A review of drugs and supplemental uses since the project’s inception shows roughly one-third of the products reviewed have been NMEs.
Incyte’s Retifanlimab Tests US FDA’s Tolerance For Low Response Rates In Accelerated Approval
US FDA advisory committee votes 13-4 to wait for Phase III data in anal cancer, expected in 2025.